Home / News
-
-
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the second quarter and first half of 2024.2024-08-02View More
-
-
QuidelOrtho Corporation (Nasdaq: QDEL) (the ¡°Company¡± or ¡°QuidelOrtho¡±), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the second quarter ended June 30, 2024.2024-08-01View More
-
-
Siemens Healthineers AG today announces its results for the third quarter of fiscal year 2024 ended June 30, 2024.2024-08-01View More
-
-
On 30 July, Information Office of Shanghai Municipality held a press briefing, introducing the details of the ¡°Several Opinions on Supporting the Innovation and Development of the Entire Biomedicine Industry Chain.¡±2024-07-31View More
-
-
Biogen Inc. (Nasdaq: BIIB), Beckman Coulter, Inc. and Fujirebio announced a collaboration to potentially identify and develop blood-based biomarkers for tau pathology in the brain and to potentially clinically advance and potentially commercialize new tests for tau pathology in Alzheimer¡¯s disease (AD). The development of tau-specific blood-based biomarkers that can measure a patient¡¯s tau burden could provide critical insights into the underlying pathological processes of AD and may help advance the development of a new generation of therapies impacting tau pathology.2024-07-31View More
-
-
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2024.2024-07-31View More
-
-
In terms of the pharmaceutical macro-political environment, the biomedical industry policies such as medical insurance cost control and target quantity procurement, are gradually implementing.2024-07-30View More
-
-
The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), examined and approved the Group¡¯s Consolidated Financial Statements at June 30, 2024.2024-07-30View More
-
-
Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended June 30, 2024.2024-07-30View More
-
-
Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.2024-07-29View More
-
-
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the completion of the acquisition of LumiraDx¡¯s Point of Care technology, following the receipt of all required antitrust and regulatory clearances. Roche will now embark on the full integration of the company¡¯s innovative multi-assay point of care platform and the related R&D, operational and commercial sites into its global organisation.2024-07-29View More
-
-
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G GFAP assay for the fully automated, random-access LUMIPULSE® G immunoassay systems. The Research Use Only (RUO) assay is now available in the United States, and it will be available in Japan, Europe and other regions* as of September this year. The Chemiluminescent Enzyme Immunoassay (CLEIA) test allows for the quantitative measurement of glial fibrillary acidic protein (GFAP) in human plasma and serum in just 35 minutes.2024-07-29View More
-
-
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a global collaboration agreement to develop, manufacture and commercialize flow cytometry-based companion diagnostics (CDx) intended to help select the best treatment for patients with cancer and other diseases.2024-07-26View More
-
-
Group sales were up by 5%1 at constant exchange rates (CER) (stable in CHF) in the first half, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by 8%2024-07-26View More
-
-
Switzerland's Saphetor said Wednesday that it has received CE marking for VarSome Clinical, its genome interpretation platform.2024-07-25View More
-
-
The US Food and Drug Administration recently granted Emergency Use Authorization for a combination COVID-19 and influenza point-of-care test developed by Nano-Ditech.2024-07-25View More
-
-
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29, 2024.2024-07-25View More
-
-
Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2024.2024-07-24View More
-
-
Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 28, 2024. All results in this release reflect only continuing operations unless otherwise noted.2024-07-24View More
-
-
Since the end of 2019, biochemical diagnosis companies have faced severe challenges due to the impact of the political and economic environment.2024-07-23View More
- CAIVD WeChat
Subscription Account
- CAIVD WeChat
Channels
China Association of In-vitro Diagnostics
Part of the information in our website is from the internet.
If by any chance it violates your rights, please contact us.